Conferences - Results from #6980

ESMO 2018: 12-Year Follow-Up of GETUG-12, A Phase 3 Trial of Docetaxel-Based Chemotherapy in High-Risk Localized Prostate Cancer October 20, 2018

ESMO 2018: Treatment of Asymptomatic or Mildly Symptomatic Chemotherapy-Naïve Patients with Bone-Predominant mCRPC October 19, 2018

ESMO 2018: ERA 223 - A Phase 3 Trial of Ra-223 in Combination with Abiraterone Acetate & Prednisone for the Treatment of Asymptomatic or Mildly Symptomatic Chemotherapy-Naïve Patients with mCRPC October 19, 2018

ESMO 2018: Cabazitaxel vs Abiraterone or Enzalutamide in Poor Prognosis Metastatic Castration-Resistant Prostate Cancer Patients October 19, 2018

ESMO 2018: A Randomized Phase 2 Study of Cabazitaxel vs Abiraterone or Enzalutamide in Poor Prognosis Metastatic Castration-Resistant Prostate Cancer October 19, 2018

ESMO 2018: Updated Results of GETUG-12, a Phase III Trial Of Docetaxel-Based Chemotherapy In High-Risk Localized Prostate Cancer, with a 12-Year Follow-Up October 19, 2018

Huge Variations Between Countries in Time for Reimbursement Decisions on New Cancer Drugs October 19, 2018

ESMO Women for Oncology Forum Focuses on Power Sharing to Foster Gender Equality October 18, 2018

Financial Impacts of Cancer Found to Intensify Disease Burden Among German Patients October 16, 2018

NSAUA 2018: Retrograde Intra-Renal Surgery for Renal Calculi: What is the Limit? October 14, 2018

NSAUA 2018: The Importance of Endoscopic Observations of the Renal Papillae October 14, 2018

NSAUA 2018: Non-Metastatic Castration Resistant Prostate Cancer October 14, 2018

NSAUA 2018: The Curability of Invasive Bladder Cancer October 13, 2018

NSAUA 2018: Is Radical Nephrectomy Even an Option in the Face of Metastatic Renal Cell Carcinoma? October 13, 2018

NSAUA 2018: The Optimal Management of Non-Muscle Invasive Bladder Cancer October 13, 2018

IBCN 2018: Longitudinal Assessment of Multiplex Patient-Specific ctDNA Biomarkers in Bladder Cancer for Diagnosis, Surveillance, and Recurrence. October 13, 2018

IBCN 2018: RBM10: A New Bladder Tumor Suppressor Gene Involved in Alternative Splicing October 13, 2018

IBCN 2018: Transcriptional Activation of Genes and Resistance to Palbociclib October 13, 2018

IBCN 2018: Molecular Markers and Clinical Outcome of Radical Cystectomy for Bladder Cancer October 13, 2018

IBCN 2018: PD-L1 Assays in Muscle-Invasive Bladder Cancer for First-Line Treatment with Atezolizumab and Pembrolizumab October 13, 2018

Page 350 of 594